Hormonal Contraception and COVID-19 Do current COVID-19 vaccines differ in efficacy in older people?

Article Sidebar

PDF (Spanish)
Published: 2021-05-06
DOI: https://doi.org/10.51987/revhospitalbaires.v41i1.67
Keywords:
older adults, vaccine, covid-19, efficacy

Main Article Content

Miriam Rozenek
Servicio de Clínica Médica. Hospital Italiano de Buenos Aires, Argentina.

Abstract

.

Downloads

Download data is not yet available.

Article Details

Issue

Vol. 41 No. 1 (2021): Revista del Hospital Italiano de Buenos Aires

Section

Ask the expert
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Author Biography

Miriam Rozenek, Servicio de Clínica Médica. Hospital Italiano de Buenos Aires, Argentina.

Médica especialista en Geriatría e Infectología.

Secretaria de la Comisión de Vacunas de la Sociedad Argentina de Infectología (SADI).

Médica de planta del Servicio de Clínica Médica, Sección Geriatría del Hospital Italiano de Buenos Aires. Argentina

How to Cite

1.
Rozenek M. Hormonal Contraception and COVID-19 Do current COVID-19 vaccines differ in efficacy in older people?. Rev Hosp Ital B.Aires [Internet]. 2021 May 6 [cited 2026 Apr. 27];41(1):33-4. Available from: https://ojs.hospitalitaliano.org.ar/index.php/revistahi/article/view/67

References

Follegati PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-478. DOI: https://doi.org/10.1016/S0140-6736(20)31604-4

Loguniv DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet.2021;397(10275):671-681. DOI: https://doi.org/10.1016/S0140-6736(21)00234-8

Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396(10267):1979-1993. DOI: https://doi.org/10.1016/S0140-6736(20)32466-1

Vaccines and Related Biological Products Advisory Committee Meeting. FDA briefing document: Janssen Ad26.COV2.S vaccine for the prevention of COVID-19 [Internet]. Silver Spring, MD: FDA; 2021 Feb 21 [citado 2021 mar 18]. Disponible en: https://www.fda.gov/media/146217/download.

Voysey M, Costa Clemens SA, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020;397(10269):99-111. DOI: https://doi.org/10.1016/S0140-6736(20)32661-1

Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;S1473-3099(20)30987-7 DOI: https://doi.org/10.1016/S1473-3099(20)30987-7